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A B S T R A C T
The role of the pulmonary veins in the initiation of atrial fibrillation has clearly been 
elucidated and has led to catheter ablation of atrial fibrillation (AF) via pulmonary 
vein isolation, currently achieved with use of radiofrequency energy. The 2011 Ameri-
can guideline update on the management of AF considers catheter ablation as a Class 
Ia indication in patients without significant structural heart disease refractory to an-
tiarrhythmic drug therapy. The 2011 update on the guidelines for the management of 
AF by the European Society of Cardiology lists catheter ablation as a class IIa recom-
mendation in patients refractory to antiarrhythmic drug therapy. Catheter ablation 
may be considered first-line therapy in a select group of patients with paroxysmal AF 
and no significant underlying structural heart disease if an experienced operator per-
forms the procedure (class IIb indication). It should be kept in mind that the single-
procedure success rate is low, with only 40%, 37% and 29% of patients remaining free 
from recurrent arrhythmias at 1, 2 and 5 years of follow-up, respectively; the success 
rates increase after two procedures to 87%, 81% and 63% at 1, 2 and 5 years. Patients 
with longstanding persistent AF have lower success rates compared with patients with 
paroxysmal or persistent AF. This article focuses on recent developments and new 
technologies currently under investigation.
Since the first report on the role of the pulmonary veins in the initiation of atrial 
fibrillation (AF), catheter ablation of AF effected via pulmonary vein isolation (PVI) 
has undergone major evolutions.1 This article will focus on recent developments and 
new technologies currently under investigation.
G U I D E L I N E S  F O R  T H E  T R E A T M E N T  O F  A T R I A L 
F I B R I L L A T I O N
The 2011 American College of Cardiology Foundation/American Heart Asso-
ciation/Heart Rhythm Society focused update on the management of AF considers 
catheter ablation as a Class IA indication in patients without significant structural heart 
disease refractory to antiarrhythmic drug therapy.2 By contrast, the 2011 update on 
the guidelines for the management of AF by the European Society of Cardiology lists 
catheter ablation as a class IIa recommendation in patients refractory to antiarrhythmic 
drug therapy.3 Catheter ablation may be considered first-line therapy in a select group 
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of patients with paroxysmal AF and no significant underlying 
structural heart disease if an experienced operator performs 
the procedure (class IIb indication).
R A D I O F R E Q U E N C Y  C A T H E T E R 
A B L A T I O N
Recently, data on 5-year follow-up results became available 
reporting on the outcome of patients undergoing ablation for 
paroxysmal and persistent or longstanding persistent AF. Hais-
saguerre et al published their 5-year follow-up data on patients 
undergoing catheter ablation of AF.4 More than a third of 
enrolled patients suffered from persistent or longstanding per-
sistent AF. The fairly high number of patients with advanced 
AF may explain the low single-procedure success rate. After 
1, 2 and 5 years of follow-up, only 40, 37 and 29% of patients 
were free from recurrent arrhythmias, respectively. After a 
median of two procedures per patient, the arrhythmia-free 
survival rate increased to 87, 81 and 63% at 1, 2 and 5 years. 
Subgroup analysis revealed that patients with longstanding per-
sistent AF were almost twice as likely to experience arrhythmia 
recurrence than patients with paroxysmal or persistent AF. 
Hence, in view of the sobering data on the results of catheter 
ablation in patients in the advanced stages of the disease, a 
preferred strategy may be an early ablative approach to pre-
vent transition into chronic forms of AF. Since AF results in 
fibrosis of the left atrium and in turn atrial fibrosis facilitates 
development of persistent AF, assessment of the extent of 
left atrial fibrosis by magnetic resonance imaging (MRI) is 
currently under investigation. Preprocedural analysis of the 
degree of atrial fibrosis may serve as a predictor for successful 
AF ablation. The Utah classification quantifies the extent of 
left atrial fibrosis (class I <5% and class IV >35% fibrosis of 
the left atrium), while its use was predictive of subsequent AF 
ablation outcome.5 Greater extent of fibrosis correlated with 
a higher rate of arrhythmia recurrence.
To date, it is unclear which strategy serves best the patient 
with longstanding persistent AF defined as continuous AF 
lasting more than 12 months. Complex fractionated atrial 
electrograms (CFAE) are thought to play an important role 
in the maintenance of AF. Nademanee et al reported high 
procedural success rate when solely targeting CFAE for the 
treatment of AF, while a similar study by Oral et al could not 
corroborate these findings.6 Three meta-analyses concluded 
that CFAE ablation provided additional benefit to PV ablation 
alone in patients with persistent AF. But, targeting CFAE will 
result in longer procedure and fluoroscopy times, as well as a 
higher number of energy applications with the potential for 
significant collateral damage.
C R Y O B A L L O O N  A B L A T I O N
The randomized, multicenter STOP AF (Sustained 
Treatment of Paroxysmal Atrial Fibrillation) was designed to 
compare the efficacy of PVI using cryoballoon ablation with 
antiarrhythmic drug therapy. Following 245 patients for 1 year, 
nearly 70% in the ablation arm were free from recurrent AF 
without the use of antiarrhythmic medication. This compared 
favorably to the medication-only group with 7.3% of patients 
still in sinus rhythm. Several European trials have shown that 
cryoballoon ablation is a viable option for patients with par-
oxysmal or short-lasting persistent AF.7 Right phrenic nerve 
palsy was the most common complication in these trials, while 
the STOP AF study reported a higher rate of 11.2%. Using 
the smaller 23-mm balloon may result in distal positioning of 
the balloon catheter within the right superior pulmonary vein 
ostium, thereby increasing the risk for inadvertent phrenic 
nerve palsy. This complication is minimized with the bigger 
28-mm balloon allowing for a more antral position along the 
right superior pulmonary vein ostium.
L A S E R  B A L L O O N  A B L A T I O N
An alternative technology based on the use of laser energy, 
the Endoscopic Ablation System (Cardiofocus, MA, USA) 
combines balloon technology with direct visualization of in-
tracardiac tissue through use of an endoscopic camera. A laser 
beam allows point-by-point lesion creation after a compliant 
balloon is wedged into the pulmonary vein facilitating direct 
balloon-to-tissue contact. As opposed to currently available 
ablation systems, the novel catheter design permits direct visu-
alization of left atrial tissue, enabling the operator for the first 
time to apply lesions in plain sight. Initial results in patients 
with paroxysmal AF are encouraging, demonstrating successful 
acute isolation in 99% of pulmonary veins and a 1-year suc-
cess rate of 60% after a single procedure off antiarrhythmic 
medication.8 The incidence of esophageal thermal lesions was 
similar (18 vs 16%), however, the severity of thermal lesions 
(ulcerations) was more pronounced in the laser balloon group.
M U L T I E L E C T R O D E  A B L A T I O N 
C A T H E T E R
The decapolar pulmonary vein ablation catheter (PVAC, 
Medtronic Ablation Frontiers, CA, USA) facilitates duty-
cycled unipolar and bipolar radiofrequency current delivery 
at the individual pulmonary vein ostium. The combination 
of unipolar and bipolar radiofrequency current facilitates 
deployment of complete circular lesions. In paroxysmal AF, 
results have been promising with 83% of treated patients 
free of recurrent AF over a 6-month follow-up period.9 Two 
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separate studies investigated the impact of AF ablation using 
irrigated radiofrequency energy, the cryoballoon catheter and 
the multielectrode catheter on the incidence of silent cerebral 
embolizations. Both studies independently found a signifi-
cantly higher rate of silent embolization on postprocedural 
MRI in those patients treated with the multielectrode catheter 
(37.5 and 38.9%, respectively).
C O N T A C T  F O R C E  S E N S I N G 
T E C H N O L O G Y
Using radiofrequency current, lesion formation will depend 
on several factors currently measured in the electrophysiology 
laboratory, such as catheter tip-to-tissue temperature, power 
and duration of energy application. While these parameters 
can be directly measured during radiofrequency current deliv-
ery, assessment of wall contact, that is, contact force between 
catheter tip and tissue, is not as straightforward. It has been 
shown previously that changes in impedance and electrogram 
amplitude correlate poorly with tissue–electrode contact. The 
importance of proper contact force becomes obvious when 
considering that insufficient contact will result in suboptimal 
lesion formation. In turn, excessive contact force may result 
in collateral tissue damage, for example, cardiac perforation 
or esophageal injury.
A novel contact force sensor embedded into the distal tip 
of a standard 7F steerable, radiofrequency ablation catheter 
(TactiCath, Endosense SA, Geneva, Switzerland) allows real-
time assessment of contact force during energy delivery.10
The SmartTouch contact force catheter by Biosense 
Webster, Inc. uses electromechanical deformation of a spring 
situated at the distal tip of the catheter for assessment of lo-
cal contact force. The catheter integrates seamlessly with the 
CARTO 3 electroanatomical mapping system.
R E M O T E  M A G N E T I C  N A V I G A T I O N  
A N D  A B L A T I O N
It has previously been shown that AF ablation using 
magnetic navigation (Stereotaxis, MO, USA) is feasible. 
Compared to conventional manual radiofrequency ablation, 
remote-controlled magnetic PVI reduces operator radiation 
exposure by one third.11 This is achieved by limiting the op-
erator’s time spent alongside the patient, since mapping and 
ablation is performed from the control room. However, total 
procedure times are still longer when compared with conven-
tional manual PVI. In order to analyze the time needed for 
individual procedural steps during magnetic ablation, patients 
were prospectively enrolled to manual or remote magnetic 
ablation. Preliminary findings confirm previous data in that 
isolation of the right inferior pulmonary vein is particularly 
challenging and time consuming.
In conclusion, pulmonary vein isolation (PVI) is the cor-
nerstone of AF catheter ablation. Although long-term results 
in patients with paroxysmal AF are encouraging, outcome data 
in patients with persistent or longstanding persistent AF high-
light the need for improvement. Alternative energy sources and 
new technologies under development may overcome current 
limitations in transmural lesion formation, heralding a new 
era in catheter ablation of AF.
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